Nonprofits are bridging R&D’s valley of death

How charitable firms such as Advancium are helping to right the market wrongs of drug development.

By Kelly Bilodeau • Jan. 4, 2023

Forks in the road lead one medical expert to a ‘game changing’ liver treatment

Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

By Alexandra Pecci • Jan. 3, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

A preview of the top trends on the minds of industry and market leaders for the new year.

By Taren Grom • Jan. 3, 2023

From chemistry to canvas: What the pharma world can learn from art

Art and science are often viewed as diametric opposites, but these industry insiders say their passion for painting blends into their pharma work. 

By Karissa Waddick • Dec. 22, 2022

WoW: What a year

A look back at some of the most inspirational quotes from the Women of the Week podcasts in 2022.

By Taren Grom • Dec. 20, 2022

With mpox cases mysteriously dwindling, scientists search for answers

Was it a public health victory? Or did mpox ‘burn itself out?’ An epidemiologist weighs in.

By Kelly Bilodeau • Dec. 19, 2022

Blood cancer cures aren’t here yet — but incremental combinations bring the field closer

A series of small successes showed promise for the future of blood cancer treatments, particularly in the arena of drug combinations.

By Michael Gibney • Dec. 19, 2022

Can pharma quit Twitter? Social strategy evolves as Musk changes the platform

A breakdown of how Twitter’s recent shifts are impacting pharma, and how the industry should navigate the platform in 2023.

By Karissa Waddick • Dec. 16, 2022

At the heart of hematology breakthroughs, a community of researchers and patients comes together

As new and advanced therapies are revealed at the annual meeting of the American Society of Hematology this week, the patients are always at the center.

By Michael Gibney • Dec. 13, 2022

The 2023 PharmaVoice Year in Preview

Here’s a look at how industry leaders are navigating the key issues of 2023.

Dec. 12, 2022

The pharma giants making the biggest strides with global drug access

A recent report ranks the top 20 pharma companies by how well they’re boosting a critical component of health equity.

By Kelly Bilodeau • Dec. 12, 2022

Spotlight on oncology drug development & its future

Learn why an informed, holistic view is needed to succeed in today’s complex and dynamic landscape.

Dec. 12, 2022

Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career

With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.

By Taren Grom • Dec. 9, 2022

Takeda’s global quest for health equity

Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.

By Taren Grom • Dec. 8, 2022

10 noteworthy pharma leadership shake-ups this year

From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.

By Karissa Waddick • Dec. 7, 2022

Chasing a ‘holy grail’ cancer gene

Omega Therapeutics’ president and CEO Mahesh Karande on its attempts to drug the elusive c-Myc gene.

By Alexandra Pecci • Dec. 6, 2022

A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’

The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug. 

By Meagan Parrish • Dec. 6, 2022

An FDA proposal could make OTC switches easier. Here’s what the industry has to say

How the FDA’s proposal to create a new OTC approval pathway could impact the pharma industry.

By Karissa Waddick • Dec. 5, 2022

AI company zeros in on compounds to treat addiction by rewiring the brain

GATC Health is driving a novel approach it believes could work for several major neurological conditions.

By Kelly Bilodeau • Dec. 5, 2022

Big passion for small biotech and its potential to address complex diseases

A conversation with Teresa Nunes, chief medical officer of Allucent.

Dec. 5, 2022

Healthcare tech’s biggest busts

The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.

By Taren Grom • Dec. 2, 2022

Non-toxic and addiction free: The promise of a new pain med

Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

By Taren Grom • Dec. 1, 2022

5 final FDA action dates to watch this year

A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake.

By Michael Gibney • Dec. 1, 2022

10 of our most popular articles in 2022

Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

By Meagan Parrish • Nov. 30, 2022

Woman of the Week: Surface Oncology’s Dr. Alison O’Neill

With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.

By Taren Grom • Nov. 30, 2022